药明康德入选《时代周刊》World’s Best Companies in Sustainable Growth 2025 榜单|可持续发展_新浪财经

▎药明康德

近日，药明康德宣布公司入选《时代周刊》“World’s Best Companies in Sustainable Growth 2025”榜单。这一认可彰显了药明康德稳健的业绩表现和对可持续发展的坚定承诺。

该榜单由国际知名媒体《时代周刊》与全球权威数据平台Statista联合推出。榜单从业绩增长（Revenue Growth）、财务稳健（Financial Stability）和环境影响（Environmental Impact）三大维度对企业进行综合分析，旨在甄选在全球范围内可持续发展方面表现出色，同时保持强劲稳健财务表现的公司。

此次入选该榜单充分印证了药明康德在业绩成长性以及在可持续发展方面的整体战略。作为创新的赋能者、客户信赖的合作伙伴以及全球健康产业的贡献者，药明康德通过独特的一体化CRDMO平台，坚持“做对的事，把事做好”的核心价值观，不断满足全球合作伙伴不断变化的需求，赋能产业创新，引领行业洞见，把握新分子机遇，在推动长期业务增长的同时，不断为行业、为客户、为病患创造价值。

与此同时，作为负责任的企业公民，药明康德积极践行对可持续发展的承诺，将先进的环境、社会及管治（ESG）理念进一步融入到公司全球运营的方方面面，不断为社会和环境带来积极的影响。

2024年，药明康德在标普全球企业可持续发展评估（S&P Global Corporate Sustainability Assessment, CSA）中获得行业最高分，位列全球“生命科学工具与服务”领域第一；同年，公司获EcoVadis企业社会责任评级“金牌”认证，连续四年入选道琼斯可持续发展指数（DJSI）并获MSCI ESG 评级AA级。2023和2024年，公司连续两年入选标普全球可持续发展年鉴和富时罗素社会责任指数系列，并同时获评Sustainalytics“行业最高评级”和“区域最高评级”企业。药明康德出色的ESG表现也受到了CDP、ISS等全球ESG评级机构的高度认可。此外，2024年，药明康德加入了“联合国全球契约组织”（United Nations Global Compact，UNGC），承诺支持全球契约十项原则；2023年，加入“科学碳目标倡议”（Science Based Targets initiative，SBTi）以减少碳排放。

展望未来，药明康德将继续坚定不移地赋能全球合作伙伴加速研发进程，持续践行可持续发展战略和举措，与产业同仁共同携手，早日实现“让天下没有难做的药，难治的病”的伟大愿景。

关于药明康德

药明康德（股票代码：603259.SH/2359.HK）为全球医药及生命科学行业提供一体化、端到端的新药研发和生产服务，在亚洲、欧洲、北美等地均设有运营基地。药明康德通过独特的“CRDMO”和“CTDMO”业务模式，不断降低研发门槛，助力客户提升研发效率，为患者带来更多突破性的治疗方案，服务范围涵盖化学药研发和生产、生物学研究、临床前测试和临床试验研发、精准医疗研发、测试和生产等领域。2024年，药明康德连续第四年被MSCI评为ESG（环境、社会及管治）AA级。目前，公司的赋能平台正承载着来自全球30多个国家的6000多家合作伙伴的研发创新项目，致力于将更多新药、好药带给全球病患，早日实现“让天下没有难做的药，难治的病”的愿景。

WuXi AppTec Listed in TIME Magazine's World's Best Companies in Sustainable Growth 2025

Shanghai, January 3, 2024 - WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life sciences industries, announced its inclusion in TIME magazine’s “World’s Best Companies in Sustainable Growth 2025” ranking. This recognition underscores WuXi AppTec’s solid business performance and unwavering commitment to sustainable development.

The “World’s Best Companies in Sustainable Growth 2025” ranking, developed by TIME, a globally renowned publisher, in partnership with Statista, a global data and business intelligence platform, is a comprehensive analysis focused on three key dimensions – Revenue Growth, Financial Stability, and Environmental Impact. The ranking aims to identify companies that excel in sustainable development while maintaining strong financial health.

WuXi AppTec's inclusion in the ranking is a testament to the company’s holistic approach to growth and sustainability. Through its unique integrated CRDMO business model, WuXi AppTec continues to meet customers’ evolving needs, follow scientific innovations, generate industry insights, capture new molecule opportunities, and drive long-term business growth.

As a responsible corporate citizen, WuXi AppTec has deepened its commitment to sustainability by integrating ESG priorities into every aspect of global operations. In 2024, WuXi AppTec ranked #1 in the Global Life Sciences Tools & Services Industry in S&P Global's Corporate Sustainability Assessment, and received a gold medal in the EcoVadis business sustainability rating. In the same year, WuXi AppTec was included in the 2024 Dow Jones Sustainability Indices (DJSI) and maintained its AA MSCI ESG rating for the fourth consecutive year. In both 2023 and 2024, WuXi AppTec was listed in the S&P Global Sustainability Yearbook and in the FTSE4Good Index Series, and was named as an Industry and Regional “Top-Rated” company by Sustainalytics. In addition, WuXi AppTec joined the United Nations Global Compact (UNGC) in 2024 to support the initiative’s ten sustainability principles and in 2023, WuXi AppTec joined the Science Based Targets initiative (SBTi) to reduce carbon emissions.

Looking ahead, WuXi AppTec remains steadfast in its mission to advance discoveries and meaningful progress for patients, moving toward a future where “every drug can be made and every disease can be treated”.

About WuXi AppTec

As a global company with operations across Asia, Europe, and North America, WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable the global pharmaceutical and life sciences industry to advance discoveries and deliver groundbreaking treatments to patients. Through its unique business models, WuXi AppTec’s integrated, end-to-end services include chemistry drug CRDMO (Contract Research, Development, and Manufacturing Organization), biology discovery, preclinical testing and clinical research services, advanced therapies CTDMO (Contract Testing, Development and Manufacturing Organization), helping customers improve the productivity of advancing healthcare products through cost-effective and efficient solutions. WuXi AppTec received an AA ESG rating from MSCI for the fourth consecutive year in 2024, and its open-access platform is enabling more than 6,000 customers from over 30 countries to improve the health of those in need – and to realize the vision that "every drug can be made and every disease can be treated."

（转自：药明康德）